On this page
How do you decide which Module 1 administrative documents to prepare?
Start with the actual application and the change being made: contact details, legal identity, sponsorship, delegated obligations or ownership. Map each consequence to its governing source and accountable owner. FDA Module 1 headings organize possible documents; they are not a universal checklist of declarations required for every submission.
Before you begin
FDA Module 1 administrative navigation. The family is a collection of different tasks, not a mandatory document checklist for every IND, NDA, ANDA or BLA.
What you will prepare: A change-specific administrative worklist with responsible evidence owners.
Sections covered in this guide (2)
Describe what changed in legal and operational terms
Start with the actor: sponsor initiating the investigation, applicant holding the marketing application, regulatory contact, U.S. agent, or CRO performing specified duties. Ask whether the legal entity remains the same and whether rights or obligations move. “Company change” is insufficient to choose a filing.
A new email address is a contact change. An IND moving to another sponsor needs a sponsorship handoff. Delegating specified IND obligations to a CRO invokes the written-transfer boundary in §312.52. An NDA or ANDA ownership transfer invokes §314.72 and, for ANDAs, §314.99. A biologic license requires the applicable licensing process; CBER SOPP 8403 describes its staff procedure. One business transaction can trigger several of these tasks.
Build the administrative packet without making every heading mandatory
Use 1.3.1 children for identity and responsibility changes; 1.3.2 for the marketing eCTD field-copy notification described by the technical guide; 1.3.3 for the separately assessed debarment certification; 1.3.4 for financial certification/disclosure; and 1.3.5 for the applicable patent or exclusivity work. A tropical-disease voucher claim has its own evidence questions in 1.3.6.
For each candidate, write the trigger, governing source, input owner, intended document and current disposition: applies, conditional, not applicable, or undetermined. Add a reason. Do not turn the absence of a file into “not applicable,” or treat a parent navigation heading as an extra declaration to sign.
Exercise: acquisition, unchanged product, new contact
Fictional exercise: a company acquires an approved NDA, keeps manufacturing unchanged and appoints a new regulatory contact. The worklist separates ownership documents, contact updates and an assessment of labeling consequences. “No manufacturing change” does not eliminate the ownership task.
Now change the fact pattern: only the same company’s corporate name changes. The legal owner confirms continuity; the worklist shifts to a name change and any affected records rather than claiming that all application rights transferred. If continuity cannot be established, leave the classification undetermined and request the legal-entity evidence.
Turn a business announcement into an actionable document plan
A statement such as “we acquired the program” leaves too much undecided for an author. Ask for the application inventory and break the announcement into facts before assigning documents.
| Confirmed fact | Preparation route | Evidence needed before closing the row |
|---|---|---|
| Same entity, new correspondence details | Name, address or contact notice | Prior/new values, role and effective date |
| Another entity will sponsor an IND | Sponsor-change coordination | Parties, continuity plan and records access |
| CRO assumes defined IND obligations | Written-transfer review | Actual scope and allocation of untransferred duties |
| NDA or ANDA rights change hands | Ownership-transfer packet | Both parties’ documents, commitments and records |
| A CBER license is affected | Applicable product-correspondence process | License/product identity and requested agency action |
Use one row per application and consequence. Add decision owner, source provision, document destination, due action, disposition and unresolved fact. A single company-wide name-change letter may not answer the different questions raised by an IND, an approved NDA and a CBER license. An “undetermined” row is useful when it states what evidence will resolve it and who will obtain that evidence.
Planning exercise: the transaction team supplies an acquisition date and a list of product names, but no application numbers or legal-entity analysis. Prepare the factual intake record; do not yet allocate all products to an ownership-transfer template. First reconcile the product list to applications and licenses, then confirm who holds each one before and after the transaction. This prevents a correct-looking packet for the wrong regulatory asset.
Use the identity and contact guide, IND sponsorship guide and marketing ownership guide for the resulting document tasks. Close the plan only when each applicable task has an owner and evidence, not merely a filename.
Your preparation checklist
0/3 checkedUse this to track your review in this visit. Checks are not saved and do not establish regulatory compliance.
Frequently asked questions
Does every heading under Module 1.3 require a separate signed document?
No. The administrative family contains different tasks with different triggers. Decide applicability from the application and governing source, and record the reason. A parent heading, an empty folder or the absence of an attachment does not establish that a declaration is required or unnecessary.
Can one acquisition trigger more than one administrative submission task?
Yes. A transaction may change application ownership, contacts, sponsorship or licensing arrangements, and may also affect other records. Identify the actual consequences for each application. An unchanged product or manufacturing process does not by itself eliminate a change in ownership or responsibility.
How is a CRO obligations transfer different from changing the IND sponsor?
A CRO transfer allocates specified sponsor obligations through a written arrangement under section 312.52. A sponsor change concerns who takes responsibility for the investigation. Identify the actual parties and scope before selecting either workflow; replacing a service provider does not automatically establish a new IND sponsor.
Sources and revisions
Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.
Regulation
21 CFR Part 312: IND responsibilities and status ↗Current part reopened September 22, 2026; relevant provisions identified in each section. Regulatory requirements, not a marketing-application rule.
Regulation
21 CFR Part 314: drug marketing applications ↗Current part reopened September 22, 2026; §§314.50, 314.53, 314.65, 314.72, 314.94, 314.99, 314.108 and 314.150–162 inspected. Not a general BLA rule.
FDA resource
CBER SOPP 8403: issuance, reissuance and voluntary revocation ↗Version 6, effective February 27, 2023; §V.C–G. CBER staff procedure, not an independent applicant regulation. PDF reopened September 22, 2026.
Technical specification
FDA eCTD v4.0 Technical Conformance Guide ↗Version 1.5, June 2026; §§2.3 and 3.1. Exact cover and revision history checked September 22, 2026. Version-specific technical recommendations.
Technical specification · placement only
FDA eCTD v4.0 comprehensive hierarchy ↗Version 2.2, February 2025. Section 1.3. A heading identifies placement, not mandatory applicability.

